Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent Kinases

[Image: see text] Inhibition of cyclin-dependent kinases (CDKs) has emerged as an attractive strategy for the development of novel oncology therapeutics. Herein is described the utilization of an in vivo screening approach with integrated efficacy and tolerability parameters to identify candidate CD...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
المؤلفون الرئيسيون: Paruch, Kamil, Dwyer, Michael P., Alvarez, Carmen, Brown, Courtney, Chan, Tin-Yau, Doll, Ronald J., Keertikar, Kerry, Knutson, Chad, McKittrick, Brian, Rivera, Jocelyn, Rossman, Randall, Tucker, Greg, Fischmann, Thierry, Hruza, Alan, Madison, Vincent, Nomeir, Amin A., Wang, Yaolin, Kirschmeier, Paul, Lees, Emma, Parry, David, Sgambellone, Nicole, Seghezzi, Wolfgang, Schultz, Lesley, Shanahan, Frances, Wiswell, Derek, Xu, Xiaoying, Zhou, Quiao, James, Ray A., Paradkar, Vidyadhar M., Park, Haengsoon, Rokosz, Laura R., Stauffer, Tara M., Guzi, Timothy J.
التنسيق: Artigo
اللغة:Inglês
منشور في: American Chemical Society 2010
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC4007794/
https://ncbi.nlm.nih.gov/pubmed/24900195
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/ml100051d
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة